Chapters
Status | Drug name | NICE TAs | Comments |
---|---|---|---|
![]() |
Atropine injection | ||
![]() |
Domperidone suppositories |
Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. |
|
![]() |
Domperidone suspension |
Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. |
|
![]() |
Domperidone tablets |
Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. |
|
![]() |
Hyoscine butylbromide injection | ||
![]() |
Hyoscine butylbromide tablets | ||
![]() |
Mebeverine tablets 135mg | ||
![]() |
Metoclopramide injections |
Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects |
|
![]() |
Metoclopramide suspension |
Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects |
|
![]() |
Metoclopramide tablets |
Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects |
|
![]() |
Peppermint oil capsules (Mintec) | ||
![]() |
Peppermint water |
Unlicensed |
|
![]() |
Propantheline |
Specialist recommendation for hyperhidrosis |